Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
March 26 2020 - 07:30AM
Dynavax Technologies Corporation (Nasdaq: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, and the Coalition for Epidemic Preparedness
Innovations (CEPI) today announced a collaboration supporting the
global effort to develop a vaccine to prevent the coronavirus
(COVID-19). Dynavax will make the Company’s proprietary toll-like
receptor 9 (TLR9) agonist adjuvant, CpG 1018TM, available for the
development of effective vaccines against COVID-19.
CpG 1018 is the adjuvant used in HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis
B vaccine approved by the U.S. Food and Drug Administration (FDA).
Dynavax developed CpG 1018 to provide an increased vaccine immune
response, which has been demonstrated in HEPLISAV-B. CpG 1018
provides a well‑developed technology and a significant safety
database, potentially accelerating the development and large-scale
manufacturing of a COVID-19 vaccine.
“Dynavax’s mission is to develop and
commercialize innovative vaccines to prevent disease and support
patients,” commented Ryan Spencer, Chief Executive Officer of
Dynavax. “We are proud to support CEPI’s efforts to address this
global public health emergency with our advanced adjuvant
technology.”
As previously announced, the CEPI initiative to
develop a vaccine to prevent COVID-19 led to the collaboration
between Dynavax and the University of Queensland, Australia.
CEPI and Dynavax will work together to identify and
coordinate engagements with entities around the world working on
COVID-19 vaccines. The focus of this collaboration is to identify
programs that could benefit from combination with CPG 1018 to
provide a more rapid or robust immune response.
About DynavaxDynavax is a
commercial stage biopharmaceutical company developing and
commercializing novel vaccines. The Company launched its first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], in February 2018, following U.S. FDA approval for
prevention of infection caused by all known subtypes of hepatitis B
virus in adults age 18 years and older. Dynavax is also
advancing CpG 1018 as a premier vaccine adjuvant through research
collaborations and partnerships. For more information, visit
www.dynavax.com and follow the company on LinkedIn.
About Coalition for Epidemic
Preparedness Innovations (CEPI)CEPI is an innovative
partnership between public, private, philanthropic, and civil
organisations, launched at Davos in 2017, to develop vaccines to
stop future epidemics. CEPI has reached over US$750 million of its
$1 billion funding target. CEPI’s priority diseases include Ebola
virus, Lassa virus, Middle East Respiratory Syndrome coronavirus,
Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also
invests in platform technologies that can be used for rapid vaccine
and immunoprophylactic development against unknown pathogens (ie,
Disease X). To date, CEPI has committed to investing over $475
million in vaccine and platform development. Learn more at
cepi.net. Follow CEPI at @CEPIvaccines.
CEPI’s work on COVID-19
The rapid global spread and unique
epidemiological characteristics of the novel coronavirus are deeply
concerning. CEPI has moved with great urgency and in coordination
with WHO, who is leading the development of a coordinated
international response. So far, CEPI has initiated 8 partnerships
to improve understanding and to develop vaccines against the novel
coronavirus. The programmes will leverage rapid response platforms
already supported by CEPI as well as new partnerships. The aim is
to advance COVID-19 vaccine candidates into clinical testing as
quickly as possible. Follow CEPI’s COVID-19 page for the
latest updates.
Forward-Looking StatementsThis
press release contains "forward-looking" statements, including
statements regarding the potential to develop a COVID-19 vaccine
and to do so on an accelerated basis. Actual results may
differ materially from those set forth in this press release due to
the risks and uncertainties inherent in vaccine research and
development, including the timing of completing development, the
results of clinical trials, and whether and when the vaccine will
be approved for use, as well as other risks detailed in the "Risk
Factors" section of our Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 as well as discussions of potential
risks, uncertainties and other important factors in our other
filings with the U.S. Securities and Exchange Commission. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available. Information on Dynavax's website at
www.dynavax.com is not incorporated by reference in our current
periodic reports with the SEC.
Contacts - DynavaxNicole Arndt,
Senior Manager, Investor
Relationsnarndt@dynavax.com510-665-7264
Derek Cole, President Investor Relations
Advisory Solutions derek.cole@IRadvisory.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024